Copyright Reports & Markets. All rights reserved.

Global Duchenne Muscular Dystrophy Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Duchenne Muscular Dystrophy Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Product
      • 1.4.2 Deflazacort
      • 1.4.3 Prednisone
      • 1.4.4 Others
    • 1.5 Market by End User
      • 1.5.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by End User
      • 1.5.2 Male
      • 1.5.3 Female
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Duchenne Muscular Dystrophy Market Size
      • 2.1.1 Global Duchenne Muscular Dystrophy Revenue 2014-2025
      • 2.1.2 Global Duchenne Muscular Dystrophy Sales 2014-2025
    • 2.2 Duchenne Muscular Dystrophy Growth Rate by Regions
      • 2.2.1 Global Duchenne Muscular Dystrophy Sales by Regions
      • 2.2.2 Global Duchenne Muscular Dystrophy Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Duchenne Muscular Dystrophy Sales by Manufacturers
      • 3.1.1 Duchenne Muscular Dystrophy Sales by Manufacturers
      • 3.1.2 Duchenne Muscular Dystrophy Sales Market Share by Manufacturers
      • 3.1.3 Global Duchenne Muscular Dystrophy Market Concentration Ratio (CR5 and HHI)
    • 3.2 Duchenne Muscular Dystrophy Revenue by Manufacturers
      • 3.2.1 Duchenne Muscular Dystrophy Revenue by Manufacturers (2014-2019)
      • 3.2.2 Duchenne Muscular Dystrophy Revenue Share by Manufacturers (2014-2019)
    • 3.3 Duchenne Muscular Dystrophy Price by Manufacturers
    • 3.4 Duchenne Muscular Dystrophy Manufacturing Base Distribution, Product Types
      • 3.4.1 Duchenne Muscular Dystrophy Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Duchenne Muscular Dystrophy Product Type
      • 3.4.3 Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Duchenne Muscular Dystrophy Sales by Product
    • 4.2 Global Duchenne Muscular Dystrophy Revenue by Product
    • 4.3 Duchenne Muscular Dystrophy Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Duchenne Muscular Dystrophy Breakdown Data by End User

    6 North America

    • 6.1 North America Duchenne Muscular Dystrophy by Countries
      • 6.1.1 North America Duchenne Muscular Dystrophy Sales by Countries
      • 6.1.2 North America Duchenne Muscular Dystrophy Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Duchenne Muscular Dystrophy by Product
    • 6.3 North America Duchenne Muscular Dystrophy by End User

    7 Europe

    • 7.1 Europe Duchenne Muscular Dystrophy by Countries
      • 7.1.1 Europe Duchenne Muscular Dystrophy Sales by Countries
      • 7.1.2 Europe Duchenne Muscular Dystrophy Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Duchenne Muscular Dystrophy by Product
    • 7.3 Europe Duchenne Muscular Dystrophy by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Duchenne Muscular Dystrophy by Countries
      • 8.1.1 Asia Pacific Duchenne Muscular Dystrophy Sales by Countries
      • 8.1.2 Asia Pacific Duchenne Muscular Dystrophy Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Duchenne Muscular Dystrophy by Product
    • 8.3 Asia Pacific Duchenne Muscular Dystrophy by End User

    9 Central & South America

    • 9.1 Central & South America Duchenne Muscular Dystrophy by Countries
      • 9.1.1 Central & South America Duchenne Muscular Dystrophy Sales by Countries
      • 9.1.2 Central & South America Duchenne Muscular Dystrophy Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Duchenne Muscular Dystrophy by Product
    • 9.3 Central & South America Duchenne Muscular Dystrophy by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Duchenne Muscular Dystrophy by Countries
      • 10.1.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Countries
      • 10.1.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Duchenne Muscular Dystrophy by Product
    • 10.3 Middle East and Africa Duchenne Muscular Dystrophy by End User

    11 Company Profiles

    • 11.1 PTC Therapeutics
      • 11.1.1 PTC Therapeutics Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 PTC Therapeutics Duchenne Muscular Dystrophy Products Offered
      • 11.1.5 PTC Therapeutics Recent Development
    • 11.2 Sarepta Therapeutics
      • 11.2.1 Sarepta Therapeutics Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Products Offered
      • 11.2.5 Sarepta Therapeutics Recent Development
    • 11.3 Others
      • 11.3.1 Others Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Others Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Others Duchenne Muscular Dystrophy Products Offered
      • 11.3.5 Others Recent Development

    12 Future Forecast

    • 12.1 Duchenne Muscular Dystrophy Market Forecast by Regions
      • 12.1.1 Global Duchenne Muscular Dystrophy Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Regions 2019-2025
    • 12.2 Duchenne Muscular Dystrophy Market Forecast by Product
      • 12.2.1 Global Duchenne Muscular Dystrophy Sales Forecast by Product 2019-2025
      • 12.2.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Product 2019-2025
    • 12.3 Duchenne Muscular Dystrophy Market Forecast by End User
    • 12.4 North America Duchenne Muscular Dystrophy Forecast
    • 12.5 Europe Duchenne Muscular Dystrophy Forecast
    • 12.6 Asia Pacific Duchenne Muscular Dystrophy Forecast
    • 12.7 Central & South America Duchenne Muscular Dystrophy Forecast
    • 12.8 Middle East and Africa Duchenne Muscular Dystrophy Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Duchenne Muscular Dystrophy Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
      The classification of duchenne muscular dystrophy includes deflazacort, prednisone and others. And the proportion of deflazacort in 2017 is about 44%.
      Duchenne muscular dystrophy is widely used by Male patients and Female patients. The most proportion of duchenne muscular dystrophy sold to Male patients, and the proportion in 2017 is about 81%.
      The global Duchenne Muscular Dystrophy market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Duchenne Muscular Dystrophy market based on company, product type, end user and key regions.

      This report studies the global market size of Duchenne Muscular Dystrophy in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Duchenne Muscular Dystrophy in these regions.
      This research report categorizes the global Duchenne Muscular Dystrophy market by top players/brands, region, type and end user. This report also studies the global Duchenne Muscular Dystrophy market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      PTC Therapeutics
      Sarepta Therapeutics
      Others

      Market size by Product
      Deflazacort
      Prednisone
      Others
      Market size by End User
      Male
      Female

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Duchenne Muscular Dystrophy market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Duchenne Muscular Dystrophy market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Duchenne Muscular Dystrophy companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Duchenne Muscular Dystrophy submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Duchenne Muscular Dystrophy are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Doses). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Duchenne Muscular Dystrophy market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now